期刊文献+

血管疾病精准医学研究模式的现状与展望

Current status and future perspectives of precision medicine research model in vascular disease
下载PDF
导出
摘要 精准医学是医学研究未来的方向,其目的在于将现有的基因组学研究进行规范、整合、共享,加速医学研究进程,提高医学研究效率,让基因组学研究的成果更快更好的服务于临床。本文回顾了腹主动脉瘤、静脉血栓栓塞症的疾病基因组学研究,氯吡格雷、华法林的药物基因组学研究的部分研究成果。精准医学已在血管疾病的筛查、诊断、药物治疗等方面有了初步的应用。各血管疾病诊疗中心共同努力,建立我国血管疾病的精准医学研究模式是未来的发展方向。 Precision medicine is the future direction of medical research. The purpose of promoting precision medicine is standardizing,integrating and sharing present achievements of genomics,accelerating the progress and improving the efficiency of medical research,and transferring the achievements of genomics on clinical application faster and better. This paper reviews the achievements of genomics on abdominal aortic aneurysm,venous thromboembolism disease,and the achievements of pharmacogenomics on warfarin and clopidogrel. The preliminary applications of precision medicine on vascular disease have already started. Establishing the precision medicine research model on vascular disease is the future direction.
出处 《中国生化药物杂志》 CAS 2016年第7期12-14,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 精准医学 基因组学 血管疾病 precision medicine genomics vascular disease
  • 相关文献

参考文献4

二级参考文献54

  • 1Liyan Miao,Jian Yang,Chenrong Huang,Zhenya Shen. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients[J] 2007,European Journal of Clinical Pharmacology(12):1135~1141
  • 2Hugo Kohnke,Kristina S?rlin,G?ran Granath,Mia Wadelius. Warfarin dose related to apolipoprotein E (APOE) genotype[J] 2005,European Journal of Clinical Pharmacology(5-6):381~388
  • 3Johnson JA,Gong L,Whirl-Carrillo M,et al.Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9and VKORC1 genotypes and warfarin dosing[J].Clin Pharmacol Ther,2011,90(4):625-629.
  • 4Lewis BC,Nair PC,Heran SS,et al.Warfarin resistance associated with genetic polymorphism of VKORC1:linking clinical response to molecular mechanism using computational modeling[J].Pharmacogenet Genomics,2015,26(1):44-50.
  • 5Caudle KE,Rettie AE,Whirl-Carrillo M,et al.Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP-2C9 and HLA-B Genotypes and Phenytoin Dosing[J].Clin Pharmacol Ther,2014,96(5):542-548.
  • 6Eun LJ,Duck Hyun R,Ho Jung J,et al.Extremely elevated internati onal normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.[J].J Korean Med Sci,2014,29(9):1317-1319.
  • 7Limdi NA,Wadelius M,Cavallari L,et al.Warfarin pharmacogenetics:a single VKORC1 polymorphism is predictive of dose across 3 racial groups[J].Blood,2010,115(18):3827-3834.
  • 8Thatte U.Association of Genetic Polymorphisms of CYP2C9and VKORC1 with Bleeding Following Warfarin:A CaseControl Study[J].Curr Clin Pharmacol,2016,11(1):62-68.
  • 9Zhang J,Tian L,Zhang Y,et al.The influence of VKORC1gene polymorphism on warfarin maintenance dosage in pediatric patients:A systematic review and meta-analysis[J].Thromb Res,2015,136(5):955-961.
  • 10Schwarz UI,Ritchie MD,Bradford Y,et al.Genetic determinants of response to warfarin during initial anticoagul ation[J].N Engl J Med,2008,358(8):999-1008.

共引文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部